1. Home
  2. HERZ vs MRKR Comparison

HERZ vs MRKR Comparison

Compare HERZ & MRKR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Herzfeld Credit Income Fund Inc.

HERZ

Herzfeld Credit Income Fund Inc.

HOLD

Current Price

$17.60

Market Cap

23.7M

Sector

Finance

ML Signal

HOLD

Logo Marker Therapeutics Inc.

MRKR

Marker Therapeutics Inc.

HOLD

Current Price

$1.66

Market Cap

27.7M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
HERZ
MRKR
Founded
N/A
1999
Country
United States
United States
Employees
N/A
N/A
Industry
Investment Managers
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
23.7M
27.7M
IPO Year
N/A
2010

Fundamental Metrics

Financial Performance
Metric
HERZ
MRKR
Price
$17.60
$1.66
Analyst Decision
Strong Buy
Analyst Count
0
1
Target Price
N/A
$10.00
AVG Volume (30 Days)
5.2K
155.7K
Earning Date
N/A
05-14-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
33.61
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
$936.27
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$1.62
$0.81
52 Week High
$19.30
$4.07

Technical Indicators

Market Signals
Indicator
HERZ
MRKR
Relative Strength Index (RSI) 66.49 58.28
Support Level $13.85 $1.33
Resistance Level $19.30 $1.74
Average True Range (ATR) 0.50 0.11
MACD 0.07 0.02
Stochastic Oscillator 89.44 69.23

Price Performance

Historical Comparison
HERZ
MRKR

About HERZ Herzfeld Credit Income Fund Inc.

Herzfeld Credit Income Fund Inc is a non-diversified, closed-end management investment company. Its primary investment objective is to maximize risk-adjusted total returns, and its secondary investment objective is to generate high current income.

About MRKR Marker Therapeutics Inc.

Marker Therapeutics Inc is a clinical-stage immuno-oncology company specializing in the development and commercialization of novel T cell-based immunotherapies and peptide-based vaccines for the treatment of hematological malignancies and solid tumor indications. The company develops product candidates from its MultiTAA T cell technology, which is based on the selective expansion of non-engineered, tumor-specific T cells that recognize tumor-associated antigens, or TAAs, which are tumor targets, and then kill tumor cells expressing those targets. These T cells are designed to recognize multiple tumor targets to produce broad spectrum anti-tumor activity. Its pipeline products include: MT-601; and MT-401-OTS.

Share on Social Networks: